Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11808900 | 0.91 | APEX1 (1.00) | APEX1ALDH1A1KDM4EGLANPC1 | |
| SCHEMBL10242653 | 0.86 | APEX1 (0.59) | APEX1ALDH1A1KDM4ENPC1GAA | |
| SCHEMBL3374638 | 0.85 | APEX1 (0.65) | APEX1ALDH1A1KDM4EGLAKMT2A | |
| SCHEMBL4621924 | 0.84 | ALDH1A1 (0.59) | APEX1ALDH1A1KDM4ENPC1GAA | |
| SCHEMBL7224645 | 0.82 | ALDH1A1 (0.88) | APEX1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3581111 | 0.82 | APEX1 (0.76) | APEX1ALDH1A1KDM4EGLANPC1 | |
| SCHEMBL11256989 | 0.81 | APEX1 (0.79) | APEX1ALDH1A1KDM4EGLANPC1 | |
| SCHEMBL2762171 | 0.81 | APEX1 (0.79) | APEX1ALDH1A1KDM4EGLANPC1 | |
| SCHEMBL4100208 | 0.81 | KDM4E (0.70) | APEX1ALDH1A1KDM4ENPC1MEN1 | |
| SCHEMBL14198903 | 0.79 | APEX1 (0.77) | APEX1ALDH1A1KDM4EGLANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | APEX1 2109/4885ALDH1A1 2972/4885KDM4E 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.